标题
Kinase Signaling in Colitis-Associated Colon Cancer and Inflammatory Bowel Disease
作者
关键词
-
出版物
Biomolecules
Volume 13, Issue 11, Pages 1620
出版商
MDPI AG
发表日期
2023-11-06
DOI
10.3390/biom13111620
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
- (2023) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
- (2023) William J Sandborn et al. LANCET
- Etrasimod for ulcerative colitis: evaluating phase III results
- (2023) Katsuyoshi Matsuoka et al. Nature Reviews Gastroenterology & Hepatology
- Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
- (2023) Ole Haagen Nielsen et al. PHARMACOLOGY & THERAPEUTICS
- Review: emerging drug therapies in inflammatory bowel disease
- (2022) Laurie B. Grossberg et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
- (2022) Wayne J. G. Hellstrom et al. ADVANCES IN THERAPY
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
- (2022) Silvio Danese et al. LANCET
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
- (2022) Geert D'Haens et al. LANCET
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
- (2022) Marc Ferrante et al. LANCET
- Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease
- (2022) Ole Haagen Nielsen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
- (2022) Balakarthikeyan Janani et al. Vaccines
- p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases
- (2022) Pilar Fajardo et al. Cancer Communications
- JAK inhibitors and VTE risk: how concerned should we be?
- (2021) Stanley B. Cohen Nature Reviews Rheumatology
- The safety of JAK-1 inhibitors
- (2021) Benjamin Clarke et al. RHEUMATOLOGY
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
- (2021) Georg Schett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting STAT3 Signaling Pathway in Colorectal Cancer
- (2021) Antonios N. Gargalionis et al. Biomedicines
- Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
- (2021) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
- (2021) Ferdinando D’Amico et al. Journal of Crohns & Colitis
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis
- (2020) Jianxin Li et al. World Journal of Surgical Oncology
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
- (2020) William J Sandborn et al. Journal of Crohns & Colitis
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2020) Michael F. Robinson et al. Arthritis & Rheumatology
- Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review
- (2020) Javier P. Gisbert et al. DRUGS
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis
- (2020) Anouk M. Wijnands et al. GASTROENTEROLOGY
- JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
- (2019) Silvio Danese et al. GUT
- Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults
- (2019) Elena M. Stoffel et al. GASTROENTEROLOGY
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- The epidemiology of inflammatory bowel disease: East meets west
- (2019) Wing Yan Mak et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting JAK-STAT signal transduction in IBD
- (2018) Christoffer Soendergaard et al. PHARMACOLOGY & THERAPEUTICS
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease
- (2017) Ole Haagen Nielsen et al. TRENDS IN MOLECULAR MEDICINE
- Novel Targeted Therapies for Inflammatory Bowel Disease
- (2017) Mehmet Coskun et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
- (2016) Zhenyu Zhong et al. CELL
- Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis
- (2016) Xiang Xue et al. Cell Metabolism
- Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress
- (2015) Kosuke Sakitani et al. BMC CANCER
- Cancers Complicating Inflammatory Bowel Disease
- (2015) Laurent Beaugerie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer
- (2014) Shruti Setia et al. BIOMEDICINE & PHARMACOTHERAPY
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Myosin Light Chain Kinase Expression Induced via Tumor Necrosis Factor Receptor 2 Signaling in the Epithelial Cells Regulates the Development of Colitis-Associated Carcinogenesis
- (2014) Masahiro Suzuki et al. PLoS One
- STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer
- (2014) Andrew V Nguyen WORLD JOURNAL OF GASTROENTEROLOGY
- Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis
- (2014) Eun Ran Kim WORLD JOURNAL OF GASTROENTEROLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Regulation of inflammation by DAPK
- (2013) Ming-Zong Lai et al. APOPTOSIS
- TNFR2 Activates MLCK-Dependent Tight Junction Dysregulation to Cause Apoptosis-Mediated Barrier Loss and Experimental Colitis
- (2013) Liping Su et al. GASTROENTEROLOGY
- Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
- (2013) Ole Haagen Nielsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammation and colorectal cancer: colitis-associated neoplasia
- (2012) Sergei I. Grivennikov Seminars in Immunopathology
- Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
- (2012) Andrew Jarnicki et al. Cell Division
- Mucins in inflammatory bowel diseases and colorectal cancer
- (2011) Yong H Sheng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2
- (2010) Sergio E. Alvarez et al. NATURE
- Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma
- (2010) Doerthe Kuester et al. PATHOLOGY RESEARCH AND PRACTICE
- Linking inflammation to cancer – A novel role for Stat3
- (2009) Matthias Ernst et al. CYTOKINE
- Autophagy in the Pathogenesis of Disease
- (2008) Beth Levine et al. CELL
- Role for sphingosine kinase 1 in colon carcinogenesis
- (2008) Toshihiko Kawamori et al. FASEB JOURNAL
- Sphingosine-1-Phosphate Mediates Transcriptional Regulation of Key Targets Associated with Survival, Proliferation, and Pluripotency in Human Embryonic Stem Cells
- (2008) Katie Avery et al. STEM CELLS AND DEVELOPMENT
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started